Loading...
XSHE
300158
Market cap920mUSD
Dec 05, Last price  
6.56CNY
1D
-0.30%
1Q
-18.00%
Jan 2017
-32.99%
IPO
-29.50%
Name

Shanxi Zhendong Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300158 chart
P/E
P/S
2.19
EPS
Div Yield, %
Shrs. gr., 5y
-0.08%
Rev. gr., 5y
-7.55%
Revenues
2.97b
-18.06%
315,260,058461,053,642528,692,888930,329,7291,281,376,8571,387,054,7871,658,490,0761,919,484,9982,262,093,0883,282,999,9753,731,602,6263,419,750,4054,398,753,6034,847,833,2145,093,776,3343,728,555,3413,626,016,1322,971,127,572
Net income
-1.33b
39,227,45659,385,85568,024,64992,088,772119,768,81991,476,89174,017,15641,958,24064,646,180203,063,920301,535,9420142,762,719262,026,7382,617,429,56400-1,328,563,928
CFO
-150m
L-21.13%
128,645,10133,184,99142,276,52232,397,2640189,400,099073,228,987151,844,461045,086,167154,477,419186,353,367221,942,198284,449,19986,308,195-189,950,976-149,822,253
Dividend
May 09, 20222.7 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, researches, develops, manufactures, and markets pharmaceutical products and Chinese medicines in China. It offers cancer drugs, cardiovascular drugs, infectious disease drugs, and respiratory drugs; antibiotics, antitumor drugs, vitamins, etc.; Chinese medicines; calcium preparations; and active pharmaceutical ingredients, as well as sells gastrointestinal drugs. The company offers its products in various dosage forms, such as large volume injections, small volume injections, powder injections, lyophilized powders, tablets, hard capsules, granules, dry suspensions, ointments, psychotropic substances, and other formulations Shanxi Zhendong Pharmaceutical Co.,Ltd is based in Changzhi, China.
IPO date
Jan 07, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT